Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

We’ve just launched End­points Ca­reers, our new prod­uct con­nect­ing em­ploy­ers and job­seek­ers. The com­pe­ti­tion for bio­phar­ma tal­ent is fierce, and giv­en the unique place End­points News has in the in­dus­try, we think our ap­proach has a few key ad­van­tages that make this a com­pelling of­fer and not just an­oth­er “job board.”

The first rea­son is that we’re an­chor­ing it to En­ter­prise, our $1,000/year paid sub­scrip­tion plan for com­pa­nies of all sizes. You can think of En­ter­prise as the “com­plete” ver­sion of End­points News. No mat­ter how large or small the com­pa­ny is, that one price un­locks pay­wall con­tent for every em­ploy­ee. No seat li­cens­es or vol­ume pric­ing. We want to make this pro­gram an easy de­ci­sion at every com­pa­ny with an in­ter­est in the bio­phar­ma world. Sev­er­al hun­dred have al­ready joined En­ter­prise, and now with End­points Ca­reers, we want to make it even more ben­e­fi­cial to join.

Start­ing to­day, we’re in­tro­duc­ing a new ben­e­fit for En­ter­prise sub­scribers: Two Fea­tured Job List­ings per year on End­points Ca­reers — an $800 val­ue. If you’re a hir­ing man­ag­er at a com­pa­ny with a valid En­ter­prise sub­scrip­tion, you have two fea­tured job post­ings wait­ing for you to re­deem — just con­tact Tom Kowal­sky tom@end­pointsnews.com on our team to get start­ed. And once you do, the list­ings will be dis­trib­uted across the en­tire End­points net­work: email, web, and so­cial. Again: we’re sell­ing the same pack­age for $800 for com­pa­nies who aren’t part of the En­ter­prise pro­gram.

The oth­er key ad­van­tage on End­points Ca­reers is our fo­cus on qual­i­ty, not quan­ti­ty.

Most “job boards” be­gin with thou­sands of job list­ings pre-filled, in an at­tempt to look busy and gain web traf­fic. We take the op­po­site view. We on­ly want re­cent jobs with the high­est rel­e­vance to our au­di­ence base. And giv­en the big traf­fic num­bers to End­points News and our re­lat­ed dis­tri­b­u­tion chan­nels, we’re able to ad­ver­tise these po­si­tions in a very ef­fec­tive way: Job seek­ers are as­sured of see­ing on­ly the high­est qual­i­ty list­ings from em­ploy­ers, while em­ploy­ers get wide air cov­er­age for their open po­si­tions with­in the elite End­points read­er­ship.

We de­signed it this way. Bio­phar­ma tends to be an in­su­lar crowd with an es­pe­cial­ly big pre­mi­um placed on re­fer­rals from in­side a net­work — which is no sur­prise in an in­dus­try that is as heav­i­ly reg­u­lat­ed and sci­ence-based as this one is. In­sti­tu­tion­al knowl­edge is held by peo­ple, not in com­pa­ny clouds or lab notes. And the net­work ef­fects gained from re­cruit­ing the right kind of ex­pe­ri­enced tal­ent who know the right peo­ple are too valu­able to be mea­sured in dol­lars. This won’t ever change. It’s a sto­ry we chron­i­cle in End­points about every com­pa­ny with am­bi­tion, time and time again.

But re­fer­rals do have their lim­its. Was the job op­por­tu­ni­ty ex­posed to the most di­verse tal­ent pool pos­si­ble? How does a found­ing team of a few fa­mil­iar faces re­cruit a work­force that can bring fresh ideas and ap­proach­es?

Ba­si­cal­ly: Did we cast a wide enough net?

End­points Ca­reers is here to help solve this is­sue: ad­ver­tis­ing bio­phar­ma op­por­tu­ni­ties with­in an elite net­work, and do­ing so on a scale that ex­pos­es it to the broad­est au­di­ence pos­si­ble.

We think that’s a com­pelling of­fer that con­tin­ues to dif­fer­en­ti­ate End­points and how we serve our read­ers. End­points Ca­reers will on­ly con­tin­ue to grow through­out the year as we in­te­grate it with our week­ly Peer Re­view col­umn. If you have any ques­tions or want to get start­ed with End­points Ca­reers, we’ve brought Tom tom@end­pointsnews.comon board as a ded­i­cat­ed client man­ag­er to help, and you can al­ways con­tact me di­rect­ly as well. So please check out End­points Ca­reers — we’re very ex­cit­ed to bring it to you.

– Ar­salan Arif
Founder & CEO, End­points News
aa@end­pointsnews.com

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.

BeiGene and Mus­tang nail down spe­cial FDA sta­tus for top drugs; Roche bags added cov­er­age for Hem­li­bra

→ BeiGene $BGNE is getting a boost in its drive to field a rival to Imbruvica. The FDA has offered an accelerated review to zanubrutinib, a BTK inhibitor that has posted positive results for mantle cell lymphoma. The PDUFA date lands on February 27, 2020. The drug scored breakthrough status at the beginning of the year.

→ BeiGene isn’t the only biopharma company to gain special regulatory status today. Mustang Bio $MBIO and St. Jude Children’s Research Hospital announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted Regenerative Medicine Advanced Therapy status.

Trump ad­min­is­tra­tion re­vives bid to get drug list prices on TV ads

The Trump administration is not giving up just yet. On Wednesday, the HHS filed an appeal against a judge’s decision in July to overturn a ruling obligating drug manufacturers to disclose the list price of their therapies in television adverts — hours before it was stipulated to go into effect.

In May, the HHS published a final ruling requiring drugmakers to divulge the wholesale acquisition cost— of a 30-day supply of the drug — in tv ads in a bid to enhance price transparency in the United States. The pharmaceutical industry has vehemently opposed the rule, asserting that list prices are not what a typical patient in the United States pays for treatment — that number is typically determined by the type of (or lack thereof) insurance coverage, deductibles and out-of-pocket costs. Although there is truth to that claim, the move was considered symbolic in the Trump administration’s healthcare agenda to hold drugmakers accountable in a climate where skyrocketing drug prices have incensed Americans on both sides of the aisle.

Ver­sant-backed Chi­nook gets a $65M launch round for its dis­cov­ery quest in a resur­gent kid­ney field

Versant is once again stepping off the beaten track in biotech to see if they can blaze a trail of their own in a field that has looked too thorny to many investors for years.

The venture group and their partners at Apple Tree are bringing their latest creation out of stealth mode today. Born in Versant’s Inception Sciences’ Chinook Therapeutics is betting that its preclinical take on kidney disease can get an early lead among the companies starting up in the field.

Sir An­drew Dil­lon, NICE's first — and on­ly — chief ex­ec­u­tive to step down next year

Using a laptop borrowed from his former employer, South London’s St George’s Hospital, Sir Andrew Dillon set about establishing NICE — launched by the then health secretary Frank Dobson — in 1999.  On Thursday, the UK cost-effectiveness watchdog said its first and only chief executive — Dillon — is stepping down in March 2020.

Back in the day, decisions about which drugs and interventions were funded by the National Health Service (NHS) were made at the local level, but this ‘postcode prescribing’ system was fraught with skewed healthcare deployment making the structure unsustainable. A national system was deemed necessary — and NICE was formed to bridge that gap.